AR106453A1 - PROGRAMMABLE UNIVERSAL CELLULAR RECEIVERS AND METHODS TO USE THE SAME - Google Patents
PROGRAMMABLE UNIVERSAL CELLULAR RECEIVERS AND METHODS TO USE THE SAMEInfo
- Publication number
- AR106453A1 AR106453A1 ARP160103236A ARP160103236A AR106453A1 AR 106453 A1 AR106453 A1 AR 106453A1 AR P160103236 A ARP160103236 A AR P160103236A AR P160103236 A ARP160103236 A AR P160103236A AR 106453 A1 AR106453 A1 AR 106453A1
- Authority
- AR
- Argentina
- Prior art keywords
- pucrs
- programmable universal
- universal cell
- methods
- same
- Prior art date
Links
Abstract
Receptores celulares universales programables (PUCRs) que comprenden una región del anticuerpo catalítico, un dominio transmembrana y un dominio citoplasmático. Los PUCRs que se divulgan aquí se pueden conjugar a un agente de especificidad para programar el receptor para conferirle especificidad para cualquier molécula de interés. También, ácidos nucleicos que codifican dichos PUCRS, y células que expresan los PUCRs. Dichas células se pueden utilizar para tratar una variedad de condiciones médicas y enfermedades que incluyen al cáncer y enfermedades infecciosas. Reivindicación 24: Una secuencia de ácido nucleico aislada que codifica un receptor celular universal programable, caracterizada porque el receptor celular universal programable comprende una secuencia de aminoácidos según se establece en la SEQ ID Nº 10.Programmable universal cell receptors (PUCRs) comprising a region of the catalytic antibody, a transmembrane domain and a cytoplasmic domain. The PUCRs disclosed herein can be conjugated to a specificity agent to program the receptor to confer specificity on any molecule of interest. Also, nucleic acids encoding said PUCRS, and cells expressing the PUCRs. Such cells can be used to treat a variety of medical conditions and diseases that include cancer and infectious diseases. Claim 24: An isolated nucleic acid sequence encoding a programmable universal cell receptor, characterized in that the programmable universal cell receptor comprises an amino acid sequence as set forth in SEQ ID No. 10.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245978P | 2015-10-23 | 2015-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106453A1 true AR106453A1 (en) | 2018-01-17 |
Family
ID=61159873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103236A AR106453A1 (en) | 2015-10-23 | 2016-10-24 | PROGRAMMABLE UNIVERSAL CELLULAR RECEIVERS AND METHODS TO USE THE SAME |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR106453A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113329769A (en) * | 2018-10-11 | 2021-08-31 | 斯克里普斯研究学院 | Antibody compounds with reactive arginine and related antibody drug conjugates |
-
2016
- 2016-10-24 AR ARP160103236A patent/AR106453A1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113329769A (en) * | 2018-10-11 | 2021-08-31 | 斯克里普斯研究学院 | Antibody compounds with reactive arginine and related antibody drug conjugates |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36961A (en) | PROGRAMMABLE UNIVERSAL CELLULAR RECEIVERS AND METHODS TO USE THE SAME | |
AU2022228122B2 (en) | Interleukin-21 muteins and methods of treatment | |
MX2019000643A (en) | Chimeric antigen receptors and methods for use. | |
MX2020004578A (en) | Casz compositions and methods of use. | |
CL2017002244A1 (en) | Specific bispecific antibodies for fap and dr5, specific antibodies for dr5 and methods of use. (divisional application 2829-2015). | |
CO2017000507A2 (en) | Chimeric bcma antigen receptor | |
MX2019012223A (en) | Anti-cd137 antibodies and methods of use thereof. | |
EA202090931A2 (en) | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING WITH HYBRID PROTEINS | |
CO2017000510A2 (en) | Car constructs | |
UY35468A (en) | CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER | |
WO2016070166A3 (en) | Messenger una molecules and uses thereof | |
PE20170704A1 (en) | THERAPEUTIC AGENT INDUCING CYTOTOXICITY | |
PE20210107A1 (en) | ANTI-CD3 ANTIBODIES AND METHODS OF USE | |
PE20170908A1 (en) | VARIANTS OF INTERFERON a2b | |
EA201790248A1 (en) | MEDIA-ANTIBODY COMPOSITIONS AND METHODS FOR THEIR RECEIVING AND APPLICATION | |
MX2019008346A (en) | T cell receptors that bind to ny-eso-1 and methods of use thereof. | |
EP4273238A3 (en) | Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity | |
AR084053A1 (en) | THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY | |
MX2019002903A (en) | Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof. | |
PE20190229A1 (en) | ANTI-FCRN ANTIBODIES | |
PE20230404A1 (en) | A CONJUGATE COMPRISING OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT, AND USE THEREOF | |
CO2018012513A2 (en) | Antibodies | |
MX2016012479A (en) | Binding members to tnf alpha. | |
PE20160528A1 (en) | ANTIBODIES | |
CL2017002729A1 (en) | Rgma binding protein and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |